Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)

Trial Profile

An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Nov 2018

At a glance

  • Drugs C2N 8E12 (Primary)
  • Indications Progressive supranuclear palsy
  • Focus Therapeutic Use
  • Sponsors AbbVie
  • Most Recent Events

    • 13 Nov 2018 Planned End Date changed from 22 Sep 2022 to 26 Sep 2022.
    • 13 Nov 2018 Planned primary completion date changed from 22 Sep 2022 to 26 Sep 2022.
    • 27 Apr 2018 Planned number of patients changed from 340 to 330.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top